A Phase 2, Double-blind, Randomized, Placebo-controlled Cross-over Study of Nelotanserin Versus Placebo in Lewy Body Dementia (LBD) Subjects Experiencing Visual Hallucinations (VH)

Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Cross-over Study of Nelotanserin Versus Placebo in Lewy Body Dementia (LBD) Subjects Experiencing Visual Hallucinations (VH)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Nelotanserin (Primary)
  • Indications Dementia; Lewy body disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 08 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Aug 2017 According to an Axovant Sciences media release, the Company expects top-line results in fourth quarter 2017.
    • 29 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top